Abstract
Vitamin D deficiency is a well-established risk factor for bone disease. Emerging data suggest a pleiotropic role of this agent in a variety of functions in humans. Epidemiological studies indicate an inverse association between vitamin D deficiency and the prevalence of cardiovascular disease (CVD), as well as individual cardiometabolic risk factors, such as hypertension, diabetes, dyslipidemia and the metabolic syndrome. Moreover, vitamin D deficiency has been implicated in the atherosclerotic process.
This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes.
Keywords: Vitamin D, cardiovascular disease, hypertension, diabetes mellitus, metabolic syndrome
Current Vascular Pharmacology
Title: Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Volume: 8 Issue: 5
Author(s): Panagiotis Anagnostis, Vasilios G. Athyros, Fotini Adamidou, Matilda Florentin and Asterios Karagiannis
Affiliation:
Keywords: Vitamin D, cardiovascular disease, hypertension, diabetes mellitus, metabolic syndrome
Abstract: Vitamin D deficiency is a well-established risk factor for bone disease. Emerging data suggest a pleiotropic role of this agent in a variety of functions in humans. Epidemiological studies indicate an inverse association between vitamin D deficiency and the prevalence of cardiovascular disease (CVD), as well as individual cardiometabolic risk factors, such as hypertension, diabetes, dyslipidemia and the metabolic syndrome. Moreover, vitamin D deficiency has been implicated in the atherosclerotic process.
This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes.
Export Options
About this article
Cite this article as:
Anagnostis Panagiotis, G. Athyros Vasilios, Adamidou Fotini, Florentin Matilda and Karagiannis Asterios, Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792006978
DOI https://dx.doi.org/10.2174/157016110792006978 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design Herb-Drug Interactions: An Evidence Based Approach
Current Medicinal Chemistry Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: Cell Immunity in Cardiovascular and Cerebrovascular Diseases)
Current Immunology Reviews (Discontinued) Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design Sustained Release of Verapamil Hydrochloride from Sodium Alginate Microcapsules
Current Drug Delivery Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Dopamine D5 Receptors: A Challenge to Medicinal Chemists
Mini-Reviews in Medicinal Chemistry Properties and Distribution of Angiotensin I Converting Enzyme
Current Pharmaceutical Design Editorial:Circulating Biomarkers in Cardiovascular Diseases – A Field of Theoretical Research or Realistic Clinical Application?
Current Pharmaceutical Biotechnology NMR Assignment and Secondary Structure of Coiled Coil Domain of C-terminal Myosin Binding Subunit of Myosin Phosphatase
Protein & Peptide Letters COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region
Current Diabetes Reviews Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery Design, Synthesis and ex vivo Study of the Vasorelaxant Activity Induced by Isosteric Derivatives of Dihydropyridines (NH→O)
Letters in Drug Design & Discovery Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets